The 36-month beta value for SNOA is at 1.36. Analysts have varying views on the stock, with 2 analysts rating it as a “buy,” 0 rating it as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for SNOA is 18.73M, and currently, shorts hold a 3.13% of that float. The average trading volume for SNOA on June 26, 2024 was 3.98M shares.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
SNOA) stock’s latest price update
Sonoma Pharmaceuticals Inc. (NASDAQ: SNOA)’s stock price has plunge by -0.84relation to previous closing price of 0.19. Nevertheless, the company has seen a -1.93% plunge in its stock price over the last five trading sessions. accesswire.com reported 2024-06-17 that Revenues increased 14% in Q4 2024 compared to Q4 2023 Gross profit margin improved 3% in FY 2024 compared to FY 2023 Net loss improved 18% in Q4 2024 compared to Q4 2023, and 6% in FY 2024 compared to FY 2023 BOULDER, CO / ACCESSWIRE / June 17, 2024 / Sonoma Pharmaceuticals, Inc. (Nasdaq:SNOA),a global healthcare leader developing and producing patented Microcyn® technology-based stabilized hypochlorous acid (HOCl) products for a wide range of applications including wound, eye, oral and nasal care, dermatological conditions, podiatry, animal health care and non-toxic disinfectants, today announced financial results for fiscal year 2024 and the fourth quarter ended March 31, 2024. “We are pleased to report continued product-related growth and reduced cash burn in both our fourth quarter and fiscal year 2024 results.
SNOA’s Market Performance
Sonoma Pharmaceuticals Inc. (SNOA) has seen a -1.93% fall in stock performance for the week, with a -4.56% decline in the past month and a 19.18% surge in the past quarter. The volatility ratio for the week is 25.14%, and the volatility levels for the past 30 days are at 18.16% for SNOA. The simple moving average for the past 20 days is -4.75% for SNOA’s stock, with a -30.78% simple moving average for the past 200 days.
SNOA Trading at 4.47% from the 50-Day Moving Average
After a stumble in the market that brought SNOA to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -84.18% of loss for the given period.
Volatility was left at 18.16%, however, over the last 30 days, the volatility rate increased by 25.14%, as shares sank -5.67% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +18.53% upper at present.
During the last 5 trading sessions, SNOA fell by -0.36%, which changed the moving average for the period of 200-days by -79.92% in comparison to the 20-day moving average, which settled at $0.1971. In addition, Sonoma Pharmaceuticals Inc. saw 4.38% in overturn over a single year, with a tendency to cut further gains.
Stock Fundamentals for SNOA
Current profitability levels for the company are sitting at:
- -0.37 for the present operating margin
- 0.37 for the gross margin
The net margin for Sonoma Pharmaceuticals Inc. stands at -0.38. The total capital return value is set at -0.42. Equity return is now at value -68.51, with -30.89 for asset returns.
Based on Sonoma Pharmaceuticals Inc. (SNOA), the company’s capital structure generated 0.09 points at debt to capital in total, while cash flow to debt ratio is standing at -3.94.
Currently, EBITDA for the company is -4.53 million with net debt to EBITDA at 0.56. When we switch over and look at the enterprise to sales, we see a ratio of 0.08. The receivables turnover for the company is 4.39for trailing twelve months and the total asset turnover is 0.86. The liquidity ratio also appears to be rather interesting for investors as it stands at 3.30.
Conclusion
In conclusion, Sonoma Pharmaceuticals Inc. (SNOA) has had a mixed performance lately. Opinion on the stock among analysts is bullish, with some giving it a “buy” rating and others a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
